Michael P. Dube - 02 Oct 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: VP, Chief Accounting Officer
Signature: /s/ James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 02 Oct 2024
Net transactions value: -$38,248
Form type: 4
Filing time: 04 Oct 2024, 17:29:43 UTC
Previous filing: 03 Jul 2024
Next filing: 07 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Sale	$38,248	-2,012	-4.1%	$19.01	47,012	02 Oct 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2024, and does not represent a volitional trade by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.01, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 2, 2024 at each separate price.

Content

Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2024, and does not represent a volitional trade by the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.01, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 2, 2024 at each separate price.